Bahl & Gaynor Inc. Has $5.66 Million Position in Kenvue Inc. (NYSE:KVUE)

Bahl & Gaynor Inc. boosted its position in Kenvue Inc. (NYSE:KVUE) by 4.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 262,992 shares of the company’s stock after buying an additional 12,082 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Kenvue were worth $5,662,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Clearstead Advisors LLC bought a new position in shares of Kenvue in the 3rd quarter valued at about $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue in the 4th quarter valued at approximately $27,000. EverSource Wealth Advisors LLC bought a new position in shares of Kenvue in the third quarter valued at $28,000. Global Retirement Partners LLC acquired a new position in Kenvue during the third quarter worth $28,000. Finally, Venturi Wealth Management LLC bought a new stake in Kenvue during the third quarter worth $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock traded down $0.16 during midday trading on Friday, reaching $18.86. The company had a trading volume of 15,451,237 shares, compared to its average volume of 16,691,828. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80. The stock has a 50 day moving average price of $19.84 and a 200-day moving average price of $20.13. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The company had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. The firm’s revenue was down 2.7% compared to the same quarter last year. Equities research analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.24%. The ex-dividend date is Tuesday, May 7th.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KVUE. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Royal Bank of Canada dropped their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. William Blair started coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating for the company. Sanford C. Bernstein assumed coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. Finally, JPMorgan Chase & Co. cut their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.